S&CO Inc. Purchases New Holdings in Privia Health Group, Inc. $PRVA

S&CO Inc. acquired a new position in shares of Privia Health Group, Inc. (NASDAQ:PRVA – Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 42,000 shares of the company’s stock, valued at approximately $1,080,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of PRVA. GAMMA Investing LLC lifted its holdings in shares of Privia Health Group by 14.0% during the second quarter. GAMMA Investing LLC now owns 4,819 shares of the company’s stock valued at $124,000 after purchasing an additional 592 shares during the last quarter. State of Alaska Department of Revenue grew its stake in shares of Privia Health Group by 1.3% in the 4th quarter. State of Alaska Department of Revenue now owns 65,747 shares of the company’s stock worth $1,558,000 after buying an additional 823 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Privia Health Group by 8.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock worth $213,000 after buying an additional 840 shares during the last quarter. ProShare Advisors LLC increased its position in Privia Health Group by 4.1% during the 4th quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock valued at $535,000 after buying an additional 898 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in Privia Health Group by 5.9% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock valued at $385,000 after buying an additional 903 shares in the last quarter. Hedge funds and other institutional investors own 94.48% of the company’s stock.

Get Privia Health Group alerts:

Privia Health Group Trading Up 1.1%

PRVA stock opened at $22.00 on Friday. The stock has a market capitalization of $2.81 billion, a PE ratio of 104.77, a price-to-earnings-growth ratio of 1.77 and a beta of 0.85. Privia Health Group, Inc. has a 12-month low of $19.53 and a 12-month high of $28.82. The stock’s 50 day simple moving average is $24.71 and its 200 day simple moving average is $23.29.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on PRVA shares. Barclays dropped their target price on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 26th. Canaccord Genuity Group set a $32.00 price target on Privia Health Group in a report on Friday, August 7th. Zacks Research raised Privia Health Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 5th. Citigroup reaffirmed a “buy” rating on shares of Privia Health Group in a research report on Thursday, July 23rd. Finally, Weiss Ratings upgraded shares of Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, July 2nd. Eleven equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $31.00.

Check Out Our Latest Research Report on Privia Health Group

Insider Buying and Selling at Privia Health Group

In other news, Director Matthew Shawn Morris sold 88,110 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $25.33, for a total transaction of $2,231,826.30. Following the transaction, the director directly owned 76,651 shares of the company’s stock, valued at $1,941,569.83. This represents a 53.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO David Mountcastle sold 24,734 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $27.50, for a total value of $680,185.00. Following the transaction, the chief financial officer directly owned 186,728 shares in the company, valued at approximately $5,135,020. The trade was a 11.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 327,886 shares of company stock valued at $8,628,256 in the last 90 days. Company insiders own 5.70% of the company’s stock.

About Privia Health Group

(Free Report)

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.

Featured Stories

• Five stocks we like better than Privia Health Group
• Is Best Buy the AI Winner Hiding in the Electronics Aisle?
• Applied Materials Beat Everything but Wall Street’s Expectations for Margins
• Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
• Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing

Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.